NanoViricides Launches Private Placement of Warrants in $6 Million Funding Deal
Reuters
Nov 15, 2025
NanoViricides Launches Private Placement of Warrants in $6 Million Funding Deal
NanoViricides Inc. has announced a private placement in connection with its recent $6 million registered direct offering. As part of the transaction, the company will issue Series A and Series B warrants to purchase up to 3,571,429 shares of common stock each to a single healthcare institutional investor. The Series A Warrants have an exercise price of $1.75 per share and will be exercisable six months after issuance, expiring two years later. The Series B Warrants have an exercise price of $2.00 per share, also exercisable after six months, and will expire 5.5 years from the issuance date. These warrants and the underlying shares are being offered in reliance on an exemption from SEC registration requirements and are not registered under the Securities Act.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-112644), on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.